Risk of severe, life-threatening birth defects caused by thalidomide.
For all people taking thalidomide:
Thalidomide must not be taken by women who are pregnant or who could become pregnant while taking this medication. Even a single dose of thalidomide taken during pregnancy can cause severe birth defects (physical problems present in the baby at birth) or death of the unborn baby. A program called Thalidomide REMS® (formerly known as the System for Thalidomide Education and Prescribing Safety [S.T.E.P.S.® ]) has been approved by the Food and Drug Administration (FDA) to make sure that pregnant women do not take thalidomide and that women do not become pregnant while taking thalidomide. All people who are prescribed thalidomide, including men and women who cannot become pregnant, must be registered with Thalidomide REMS® , have a thalidomide prescription from a doctor who is registered with Thalidomide REMS ® , and have the prescription filled at a pharmacy that is registered with Thalidomide REMS ® in order to receive this medication.
You will need to see your doctor every month during your treatment to talk about your condition and any side effects you may be experiencing. At each visit, your doctor may give you a prescription for up to a 28-day supply of medication with no refills. You must have this prescription filled within 7 days.
Do not donate blood while you are taking thalidomide and for 4 weeks after your treatment.
Do not share thalidomide with anyone else, even someone who may have the same symptoms that you have.
For women taking thalidomide:
If you can become pregnant, you will need to meet certain requirements during your treatment with thalidomide. You need to meet these requirements even if you have a history of not being able to become pregnant. You may be excused from meeting these requirements only if you have not menstruated (had a period) for 24 months in a row, or you have had a hysterectomy (surgery to remove your uterus).
You must use two acceptable forms of birth control for 4 weeks before you begin to take thalidomide, during your treatment, and for 4 weeks after your treatment. Your doctor will tell you which forms of birth control are acceptable. You must use these two forms of birth control at all times unless you can guarantee that you will not have any sexual contact with a male for 4 weeks before your treatment, during your treatment, and for 4 weeks after your treatment.
Some medications can cause hormonal contraceptives to be less effective. If you plan to use hormonal contraceptives (birth control pills, patches, implants, injections, rings, or intrauterine devices) during your treatment with thalidomide, tell your doctor about all the medications, vitamins, and herbal supplements you are taking or plan to take. Be sure to mention: griseofulvin (Grifulvin); certain medications to treat human immunodeficiency virus (HIV) including amprenavir (Agenerase), atazanavir (Reyataz), darunavir (Prezista), fosamprenavir (Lexiva), indinavir (Crixivan), lopinavir (in Kaletra), nelfinavir (Viracept), ritonavir (Norvir, in Kaletra), saquinavir (Invirase), and tipranavir (Aptivus); certain medications for seizures including carbamazepine (Carbatrol, Equetro, Tegretol) and phenytoin (Dilantin, Phenytek); modafinil (Provigil); penicillin; rifampin (Rimactane, Rifadin); rifabutin (Mycobutin); and St. John's wort. Many other medications may interfere with the action of hormonal contraceptives, so be sure to tell your doctor all of the medications you are taking or plan to take, even those that do not appear on this list.
You must have two negative pregnancy tests before you can begin to take thalidomide. You will also need to be tested for pregnancy in a laboratory at certain times during your treatment. Your doctor will tell you when and where to have these tests.
Stop taking thalidomide and call your doctor right away if you think you are pregnant, you have a late, irregular, or missed menstrual period, you have any change in your menstrual bleeding, or you have sex without using two forms of birth control. In some cases, your doctor can prescribe emergency contraception ('the morning after pill') to prevent pregnancy. If you become pregnant during your treatment, your doctor is required to call the FDA and the manufacturer. Your doctor will also make sure you talk with a doctor who specializes in problems during pregnancy who can help you make choices that are best for you and your baby.
For men taking thalidomide:
Thalidomide is present in semen (fluid containing sperm that is released through the penis during orgasm). You must either use a latex or synthetic condom or completely avoid any sexual contact with a woman who is pregnant or may become pregnant while you are taking this medication and for 4 weeks after your treatment. This is required even if you have had a vasectomy (surgery to prevent sperm from leaving your body and causing pregnancy). Tell your doctor immediately if you have had unprotected sex with a woman who can become pregnant or if you think for any reason that your partner is pregnant.
Do not donate semen or sperm while you are taking thalidomide and for 4 weeks after your treatment.
Risk of blood clots:
If you are taking thalidomide to treat multiple myeloma (a type of cancer of the bone marrow), there is a risk that you will develop a blood clot in your arms, legs or lungs. This risk is greater when thalidomide is used along with other chemotherapy medications such as dexamethasone. Call your doctor immediately if you experience any of the following symptoms: pain, tenderness, redness, warmth, or swelling in the arms or legs; shortness of breath; or chest pain. Your doctor may prescribe an anticoagulant ('blood thinner') or aspirin to help stop clots from forming during your treatment with thalidomide.
Talk to your doctor about the risks of taking thalidomide.
Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.
Thalidomide comes as a capsule to take by mouth. Thalidomide is usually taken with water once a day at bedtime and at least 1 hour after an evening meal. If you are taking thalidomide to treat ENL, your doctor may tell you to take it more than once a day, at least 1 hour after meals. Take thalidomide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take thalidomide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Keep the capsules in their packaging until you are ready to take them. Do not open the capsules or handle them more than necessary. If your skin comes into contact with broken capsules or powder, wash the exposed area with soap and water.
The length of your treatment depends on how your symptoms respond to thalidomide and whether your symptoms return when you stop taking the medication. Your doctor may need to interrupt your treatment or reduce your dose if you experience certain side effects. Do not stop taking thalidomide without talking to your doctor. When your treatment is complete your doctor will probably decrease your dose gradually.
Thalidomide is also sometimes used to treat certain skin conditions involving swelling and irritation. It is also used to treat certain complications of human immunodeficiency virus (HIV) such as aphthous stomatitis (condition in which ulcers form in the mouth), HIV-associated diarrhea, HIV-associated wasting syndrome, certain infections, and Kaposi's sarcoma (a type of skin cancer). Thalidomide has also been used to treat some types of cancer and tumors, severe weight loss in patients with weakened immune systems, chronic graft versus host disease (a complication that can occur after a bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body), and Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever). Talk to your doctor about the risks of using this medication for your condition.
This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Before taking thalidomide,
Unless your doctor tells you otherwise, continue your normal diet.
Take the missed dose as soon as you remember it. However, if it is less than 12 hours until your next scheduled dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Thalidomide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately or get emergency medical treatment:
Thalidomide may cause nerve damage that can be severe and permanent. This damage may occur any time during or after your treatment. Your doctor will examine you regularly to see how thalidomide has affected your nervous system. If you experience any of the following symptoms, stop taking thalidomide and call your doctor immediately: numbness, tingling, pain, or burning in the hands and feet.
Thalidomide may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( Web Site ) or by phone (1-800-332-1088).
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. Web Site
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website ( Web Site) for more information if you do not have access to a take-back program.
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at Web Site. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to thalidomide.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: August 15, 2019.